Non-Small Cell Lung Cancer - Pipeline Review, H1 2014


#196409

1359pages

Global Markets Direct

$ 2500

In Stock

Non-Small Cell Lung Cancer Pipeline Review, H1 2014, provides an overview of the Non-Small Cell Lung Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Non-Small Cell Lung Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
Introduction 10
Non-Small Cell Lung Cancer Overview 11
Therapeutics Development 12
Non-Small Cell Lung Cancer - Therapeutics under Development by Companies 14
Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 30
Non-Small Cell Lung Cancer - Pipeline Products Glance 34
Non-Small Cell Lung Cancer - Products under Development by Companies 38
Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes 60
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 62
Non-Small Cell Lung Cancer - Therapeutics Assessment 241
Drug Profiles 276
Non-Small Cell Lung Cancer - Recent Pipeline Updates 959
Non-Small Cell Lung Cancer - Dormant Projects 1288
Non-Small Cell Lung Cancer - Discontinued Products 1304
Non-Small Cell Lung Cancer - Product Development Milestones 1309

Appendix 1319

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2014 51
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H1 2014 52
Number of Products under Development by Companies, H1 2014 54
Number of Products under Development by Companies, H1 2014 (Contd..1) 55
Number of Products under Development by Companies, H1 2014 (Contd..2) 56
Number of Products under Development by Companies, H1 2014 (Contd..3) 57
Number of Products under Development by Companies, H1 2014 (Contd..4) 58
Number of Products under Development by Companies, H1 2014 (Contd..5) 59
Number of Products under Development by Companies, H1 2014 (Contd..6) 60
Number of Products under Development by Companies, H1 2014 (Contd..7) 61
Number of Products under Development by Companies, H1 2014 (Contd..8) 62
Number of Products under Development by Companies, H1 2014 (Contd..9) 63
Number of Products under Development by Companies, H1 2014 (Contd..10) 64
Number of Products under Development by Companies, H1 2014 (Contd..11) 65
Number of Products under Development by Companies, H1 2014 (Contd..12) 66
Number of Products under Development by Companies, H1 2014 (Contd..13) 67
Number of Products under Development by Companies, H1 2014 (Contd..14) 68
Number of Products under Investigation by Universities/Institutes, H1 2014 70
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 71
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 72
Comparative Analysis by Late Stage Development, H1 2014 73
Comparative Analysis by Clinical Stage Development, H1 2014 74
Comparative Analysis by Early Stage Development, H1 2014 75
Comparative Analysis by Unknown Stage Development, H1 2014 76
Products under Development by Companies, H1 2014 77
Products under Development by Companies, H1 2014 (Contd..1) 78
Products under Development by Companies, H1 2014 (Contd..2) 79
Products under Development by Companies, H1 2014 (Contd..3) 80
Products under Development by Companies, H1 2014 (Contd..4) 81
Products under Development by Companies, H1 2014 (Contd..5) 82
Products under Development by Companies, H1 2014 (Contd..6) 83
Products under Development by Companies, H1 2014 (Contd..7) 84
Products under Development by Companies, H1 2014 (Contd..8) 85
Products under Development by Companies, H1 2014 (Contd..9) 86
Products under Development by Companies, H1 2014 (Contd..10) 87
Products under Development by Companies, H1 2014 (Contd..11) 88
Products under Development by Companies, H1 2014 (Contd..12) 89
Products under Development by Companies, H1 2014 (Contd..13) 90
Products under Development by Companies, H1 2014 (Contd..14) 91
Products under Development by Companies, H1 2014 (Contd..15) 92
Products under Development by Companies, H1 2014 (Contd..16) 93
Products under Development by Companies, H1 2014 (Contd..17) 94
Products under Development by Companies, H1 2014 (Contd..18) 95
Products under Development by Companies, H1 2014 (Contd..19) 96
Products under Development by Companies, H1 2014 (Contd..20) 97
Products under Development by Companies, H1 2014 (Contd..21) 98
Products under Investigation by Universities/Institutes, H1 2014 99
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 100
Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2014 101
Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 102
Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 103
Non-Small Cell Lung Cancer - Pipeline by Helix BioPharma Corp.,H1 2014 104
Non-Small Cell Lung Cancer - Pipeline by Amgen Inc., H1 2014 105
Non-Small Cell Lung Cancer - Pipeline by Sanofi, H1 2014 106
Non-Small Cell Lung Cancer - Pipeline by AstraZeneca PLC, H1 2014 107
Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2014 108
Non-Small Cell Lung Cancer - Pipeline by Viralytics Ltd., H1 2014 109
Non-Small Cell Lung Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 110
Non-Small Cell Lung Cancer - Pipeline by Genentech, Inc., H1 2014 111
Non-Small Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2014 112
Non-Small Cell Lung Cancer - Pipeline by MedImmune, LLC, H1 2014 113
Non-Small Cell Lung Cancer - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 114
Non-Small Cell Lung Cancer - Pipeline by Gilead Sciences, Inc., H1 2014 115
Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 116
Non-Small Cell Lung Cancer - Pipeline by Merck & Co., Inc., H1 2014 117
Non-Small Cell Lung Cancer - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 118
Non-Small Cell Lung Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 119
Non-Small Cell Lung Cancer - Pipeline by BioLineRx, Ltd., H1 2014 120
Non-Small Cell Lung Cancer - Pipeline by Piramal Enterprises Limited, H1 2014 121
Non-Small Cell Lung Cancer - Pipeline by Celltrion, Inc., H1 2014 122
Non-Small Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 123
Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H1 2014 124
Non-Small Cell Lung Cancer - Pipeline by Samyang Holdings Corporation, H1 2014 125
Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H1 2014 126
Non-Small Cell Lung Cancer - Pipeline by Biocon Limited, H1 2014 127
Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 128
Non-Small Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H1 2014 129
Non-Small Cell Lung Cancer - Pipeline by ImmunoGen, Inc., H1 2014 130
Non-Small Cell Lung Cancer - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 131
Non-Small Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 132
Non-Small Cell Lung Cancer - Pipeline by Pfizer Inc., H1 2014 133
Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 134
Non-Small Cell Lung Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 135
Non-Small Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 136
Non-Small Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 137
Non-Small Cell Lung Cancer - Pipeline by Cell Therapeutics, Inc., H1 2014 138
Non-Small Cell Lung Cancer - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 139
Non-Small Cell Lung Cancer - Pipeline by Exelixis, Inc., H1 2014 140
Non-Small Cell Lung Cancer - Pipeline by Aduro BioTech, Inc., H1 2014 141
Non-Small Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 142
Non-Small Cell Lung Cancer - Pipeline by Cyclacel Pharmaceuticals Inc., H1 2014 143
Non-Small Cell Lung Cancer - Pipeline by Celgene Corporation, H1 2014 144
Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2014 145
Non-Small Cell Lung Cancer - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2014 146
Non-Small Cell Lung Cancer - Pipeline by Merck KGaA, H1 2014 147
Non-Small Cell Lung Cancer - Pipeline by 4SC AG., H1 2014 148
Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2014 149
Non-Small Cell Lung Cancer - Pipeline by Immunomedics, Inc., H1 2014 150
Non-Small Cell Lung Cancer - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 151
Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 152
Non-Small Cell Lung Cancer - Pipeline by Lorus Therapeutics Inc., H1 2014 153
Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2014 154
Non-Small Cell Lung Cancer - Pipeline by Benitec Biopharma Limited, H1 2014 155
Non-Small Cell Lung Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2014 156
Non-Small Cell Lung Cancer - Pipeline by Oncolytics Biotech Inc., H1 2014 157
Non-Small Cell Lung Cancer - Pipeline by Compugen Ltd., H1 2014 158
Non-Small Cell Lung Cancer - Pipeline by OXiGENE, Inc., H1 2014 159
Non-Small Cell Lung Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 160
Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2014 161
Non-Small Cell Lung Cancer - Pipeline by ArQule, Inc., H1 2014 162
Non-Small Cell Lung Cancer - Pipeline by Mast Therapeutics, Inc., H1 2014 163
Non-Small Cell Lung Cancer - Pipeline by Telik, Inc., H1 2014 164
Non-Small Cell Lung Cancer - Pipeline by Topotarget A/S, H1 2014 165
Non-Small Cell Lung Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2014 166
Non-Small Cell Lung Cancer - Pipeline by Pharmacyclics, Inc., H1 2014 167
Non-Small Cell Lung Cancer - Pipeline by Dendreon Corporation, H1 2014 168
Non-Small Cell Lung Cancer - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 170
Non-Small Cell Lung Cancer - Pipeline by Mologen AG, H1 2014 171
Non-Small Cell Lung Cancer - Pipeline by Quest PharmaTech Inc., H1 2014 172
Non-Small Cell Lung Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 173
Non-Small Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014 174
Non-Small Cell Lung Cancer - Pipeline by Panacea Biotec Limited, H1 2014 175
Non-Small Cell Lung Cancer - Pipeline by Natco Pharma Limited, H1 2014 176
Non-Small Cell Lung Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2014 177
Non-Small Cell Lung Cancer - Pipeline by Oscotec Inc., H1 2014 178
Non-Small Cell Lung Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2014 179
Non-Small Cell Lung Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2014 180
Non-Small Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2014 181
Non-Small Cell Lung Cancer - Pipeline by Morphotek, Inc., H1 2014 182
Non-Small Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 183
Non-Small Cell Lung Cancer - Pipeline by Debiopharm International S.A., H1 2014 184
Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2014 185
Non-Small Cell Lung Cancer - Pipeline by Supratek Pharma Inc., H1 2014 186
Non-Small Cell Lung Cancer - Pipeline by Ganymed Pharmaceuticals AG, H1 2014 187
Non-Small Cell Lung Cancer - Pipeline by Ora Bio Ltd., H1 2014 188
Non-Small Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2014 189
Non-Small Cell Lung Cancer - Pipeline by NovaRx Corporation, H1 2014 190
Non-Small Cell Lung Cancer - Pipeline by TheRyte Ltd., H1 2014 191
Non-Small Cell Lung Cancer - Pipeline by Priaxon AG, H1 2014 192
Non-Small Cell Lung Cancer - Pipeline by Cadila Pharmaceuticals Ltd., H1 2014 193
Non-Small Cell Lung Cancer - Pipeline by Hutchison MediPharma Limited, H1 2014 194
Non-Small Cell Lung Cancer - Pipeline by Vaxon Biotech, H1 2014 195
Non-Small Cell Lung Cancer - Pipeline by CureVac GmbH, H1 2014 196
Non-Small Cell Lung Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2014 197
Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corporation, H1 2014 198
Non-Small Cell Lung Cancer - Pipeline by Heat Biologics, Inc., H1 2014 199
Non-Small Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014 200
Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H1 2014 201
Non-Small Cell Lung Cancer - Pipeline by Azaya Therapeutics Incorporated, H1 2014 202
Non-Small Cell Lung Cancer - Pipeline by CanBas Co., Ltd., H1 2014 203
Non-Small Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 204
Non-Small Cell Lung Cancer - Pipeline by Neotropix, Inc., H1 2014 205
Non-Small Cell Lung Cancer - Pipeline by Mersana Therapeutics, Inc., H1 2014 206
Non-Small Cell Lung Cancer - Pipeline by Reata Pharmaceuticals, Inc., H1 2014 207
Non-Small Cell Lung Cancer - Pipeline by Axelar AB, H1 2014 208
Non-Small Cell Lung Cancer - Pipeline by Endocyte, Inc., H1 2014 209
Non-Small Cell Lung Cancer - Pipeline by Proacta, Inc., H1 2014 210
Non-Small Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2014 211
Non-Small Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2014 212
Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2014 213
Non-Small Cell Lung Cancer - Pipeline by MolMed S.p.A., H1 2014 214
Non-Small Cell Lung Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2014 215
Non-Small Cell Lung Cancer - Pipeline by Globeimmune, Inc., H1 2014 216
Non-Small Cell Lung Cancer - Pipeline by Immunocore Limited, H1 2014 217
Non-Small Cell Lung Cancer - Pipeline by Immune Design Corp., H1 2014 218
Non-Small Cell Lung Cancer - Pipeline by Bind Therapeutics, Inc., H1 2014 219
Non-Small Cell Lung Cancer - Pipeline by NewLink Genetics Corporation., H1 2014 220
Non-Small Cell Lung Cancer - Pipeline by Xcovery, Inc., H1 2014 221
Non-Small Cell Lung Cancer - Pipeline by Pharma Mar, S.A., H1 2014 222
Non-Small Cell Lung Cancer - Pipeline by Quintessence Biosciences, Inc., H1 2014 223
Non-Small Cell Lung Cancer - Pipeline by Sirnaomics, Inc., H1 2014 224
Non-Small Cell Lung Cancer - Pipeline by Biothera, Inc., H1 2014 225
Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2014 226
Non-Small Cell Lung Cancer - Pipeline by Medisyn Technologies, Inc., H1 2014 227
Non-Small Cell Lung Cancer - Pipeline by Golden Biotechnology Corp., H1 2014 228
Non-Small Cell Lung Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2014 229
Non-Small Cell Lung Cancer - Pipeline by Pique Therapeutics, H1 2014 230
Non-Small Cell Lung Cancer - Pipeline by Arch Biopartners, Inc., H1 2014 231
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., H1 2014 232
Non-Small Cell Lung Cancer - Pipeline by Clovis Oncology, Inc., H1 2014 233
Non-Small Cell Lung Cancer - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2014 234
Non-Small Cell Lung Cancer - Pipeline by ImmunoFrontier, Inc., H1 2014 235
Non-Small Cell Lung Cancer - Pipeline by Zyngenia, Inc., H1 2014 236
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2014 237
Non-Small Cell Lung Cancer - Pipeline by Recombio, H1 2014 238
Non-Small Cell Lung Cancer - Pipeline by NuCana BioMed Limited, H1 2014 239
Non-Small Cell Lung Cancer - Pipeline by Medical Enzymes AG, H1 2014 240
Non-Small Cell Lung Cancer - Pipeline by KAEL-GemVax Co., Ltd., H1 2014 241
Non-Small Cell Lung Cancer - Pipeline by iCeutica, Inc., H1 2014 242
Non-Small Cell Lung Cancer - Pipeline by Aura Biosciences, Inc., H1 2014 243
Non-Small Cell Lung Cancer - Pipeline by Incuron, LLC, H1 2014 244
Non-Small Cell Lung Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2014 245
Non-Small Cell Lung Cancer - Pipeline by Polaris Group, H1 2014 246
Non-Small Cell Lung Cancer - Pipeline by Vichem Chemie Research Ltd., H1 2014 247
Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC, Inc., H1 2014 248
Non-Small Cell Lung Cancer - Pipeline by Regulon Inc., H1 2014 249
Non-Small Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2014 250
Non-Small Cell Lung Cancer - Pipeline by SignPath Pharma Inc, H1 2014 251
Non-Small Cell Lung Cancer - Pipeline by Oncozyme Pharma Inc., H1 2014 252
Non-Small Cell Lung Cancer - Pipeline by Optimum Therapeutics, LLC, H1 2014 253
Non-Small Cell Lung Cancer - Pipeline by BerGenBio AS, H1 2014 254
Non-Small Cell Lung Cancer - Pipeline by GlycaNova Norway AS, H1 2014 255
Non-Small Cell Lung Cancer - Pipeline by Intezyne, Inc, H1 2014 256
Non-Small Cell Lung Cancer - Pipeline by Immunome Inc., H1 2014 257
Non-Small Cell Lung Cancer - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 258
Non-Small Cell Lung Cancer - Pipeline by centrose llc, H1 2014 259
Non-Small Cell Lung Cancer - Pipeline by Verastem, Inc., H1 2014 260
Non-Small Cell Lung Cancer - Pipeline by Neopharm Co., Ltd., H1 2014 261
Non-Small Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 262
Non-Small Cell Lung Cancer - Pipeline by X-BODY BioSciences, Inc., H1 2014 263
Non-Small Cell Lung Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H1 2014 264
Non-Small Cell Lung Cancer - Pipeline by Vaxeal Holding SA, H1 2014 265
Non-Small Cell Lung Cancer - Pipeline by Netris Pharma S.A.S., H1 2014 266
Non-Small Cell Lung Cancer - Pipeline by Conkwest, Inc., H1 2014 267
Non-Small Cell Lung Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H1 2014 268
Non-Small Cell Lung Cancer - Pipeline by Allinky Biopharma, H1 2014 269
Non-Small Cell Lung Cancer - Pipeline by Puma Biotechnology, Inc., H1 2014 270
Non-Small Cell Lung Cancer - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 271
Non-Small Cell Lung Cancer - Pipeline by Targovax AS, H1 2014 272
Non-Small Cell Lung Cancer - Pipeline by NobelProcera Innovation Centre, Quebec, H1 2014 273
Non-Small Cell Lung Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 274
Non-Small Cell Lung Cancer - Pipeline by Eagle Pharmaceuticals, Inc., H1 2014 275
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2014 276
Non-Small Cell Lung Cancer - Pipeline by DormaTarg, Inc., H1 2014 277
Non-Small Cell Lung Cancer - Pipeline by Oncology Research International Limited, H1 2014 278
Non-Small Cell Lung Cancer - Pipeline by AlphaMab Co., Ltd, H1 2014 279
Assessment by Monotherapy Products, H1 2014 280
Assessment by Combination Products, H1 2014 281
Number of Products by Stage and Target, H1 2014 284
Number of Products by Stage and Mechanism of Action, H1 2014 297
Number of Products by Stage and Route of Administration, H1 2014 310
Number of Products by Stage and Molecule Type, H1 2014 313
Non-Small Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2014 998
Non-Small Cell Lung Cancer - Dormant Projects, H1 2014 1327
Non-Small Cell Lung Cancer - Dormant Projects (Contd..1), H1 2014 1328
Non-Small Cell Lung Cancer - Dormant Projects (Contd..2), H1 2014 1329
Non-Small Cell Lung Cancer - Dormant Projects (Contd..3), H1 2014 1330
Non-Small Cell Lung Cancer - Dormant Projects (Contd..4), H1 2014 1331
Non-Small Cell Lung Cancer - Dormant Projects (Contd..5), H1 2014 1332
Non-Small Cell Lung Cancer - Dormant Projects (Contd..6), H1 2014 1333
Non-Small Cell Lung Cancer - Dormant Projects (Contd..7), H1 2014 1334
Non-Small Cell Lung Cancer - Dormant Projects (Contd..8), H1 2014 1335
Non-Small Cell Lung Cancer - Dormant Projects (Contd..9), H1 2014 1336
Non-Small Cell Lung Cancer - Dormant Projects (Contd..10), H1 2014 1337
Non-Small Cell Lung Cancer - Dormant Projects (Contd..11), H1 2014 1338
Non-Small Cell Lung Cancer - Dormant Projects (Contd..12), H1 2014 1339
Non-Small Cell Lung Cancer - Dormant Projects (Contd..13), H1 2014 1340
Non-Small Cell Lung Cancer - Dormant Projects (Contd..14), H1 2014 1341
Non-Small Cell Lung Cancer - Dormant Projects (Contd..15), H1 2014 1342
Non-Small Cell Lung Cancer - Discontinued Products, H1 2014 1343
Non-Small Cell Lung Cancer - Discontinued Products (Contd..1), H1 2014 1344
Non-Small Cell Lung Cancer - Discontinued Products (Contd..2), H1 2014 1345
Non-Small Cell Lung Cancer - Discontinued Products (Contd..3), H1 2014 1346
Non-Small Cell Lung Cancer - Discontinued Products (Contd..4), H1 2014 1347

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2014 51
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H1 2014 52
Number of Products under Development by Companies, H1 2014 53
Number of Products under Investigation by Universities/Institutes, H1 2014 69
Comparative Analysis by Late Stage Development, H1 2014 73
Comparative Analysis by Clinical Stage Development, H1 2014 74
Comparative Analysis by Early Stage Products, H1 2014 75
Assessment by Monotherapy Products, H1 2014 280
Assessment by Combination Products, H1 2014 281
Number of Products by Top 10 Target, H1 2014 282
Number of Products by Stage and Top 10 Target, H1 2014 283
Number of Products by Top 10 Mechanism of Action, H1 2014 295
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 296
Number of Products by Top 10 Route of Administration, H1 2014 308
Number of Products by Stage and Top 10 Route of Administration, H1 2014 309
Number of Products by Top 10 Molecule Type, H1 2014 311
Number of Products by Stage and Top 10 Molecule Type, H1 2014 312